Ceftaroline fosamil for treatment of communityacquired pneumonia: findings from FOCUS 1 and 2 and potential role in therapy

References

• Jackson ML, Neuzil KM, Thompson WW et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin. Infect. Dis.39(11), 1642–1650 (2004).
   PubMed Web of Science ®Google Scholar
• Jones RN, Jacobs MR, Sader HS. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Int. J. Antimicrob. Agents36(3), 197–204 (2010).
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society Consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis.44(Suppl. 2), S27–S72 (2007).
   PubMed Web of Science ®Google Scholar
• Richter SS, Heilmann KP, Dohrn CL, Riahi F, Beekmann SE, Doern GV. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004–2005. Clin. Infect. Dis.48(3), e23–e33 (2009).
   PubMed Web of Science ®Google Scholar
• Gertz RE, Li Z, Pimenta FC et al. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J. Infect. Dis.201(5), 770–775 (2010).
   PubMed Web of Science ®Google Scholar
• Patel SN, Pillai DR, Pong-Porter S, McGeer A, Green K, Low DE. In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008. J. Antimicrob. Chemother.64(3), 659–660 (2009).
   PubMed Web of Science ®Google Scholar
• Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.Antimicrob. Agents Chemother.54(5), 1670–1677 (2010).
   PubMed Web of Science ®Google Scholar
• Villegas-Estrada A, Lee M, Hesek D, Vakulenko SB, Mobashery S. Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA β-lactam antibiotics. J. Am. Chem. Soc.130(29), 9212–9213 (2008).
   PubMed Web of Science ®Google Scholar
• Brown SD, Traczewski MM. In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob. Agents Chemother.53(3), 1271–1274 (2009).
   PubMed Web of Science ®Google Scholar
• Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ. In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria. Antimicrob. Agents Chemother.54(4), 1627–1632 (2010).
   PubMed Web of Science ®Google Scholar
• Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob. Agents Chemother.51(10), 3612–3616 (2007).
   PubMed Web of Science ®Google Scholar
• Corey GR, Wilcox M, Talbot GH et al. Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin. Infect. Dis.51(6), 641–650 (2010).
   PubMed Web of Science ®Google Scholar
• File TM Jr, Low DE, Eckburg PB et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled blinded, multicenter Phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin. Infect. Dis.51(12), 1395–1405 (2010).
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Bajaksouzian S, Zilles A, Lin G, Pankuch GA, Appelbaum PC. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study. Antimicrob. Agents Chemother.43(8), 1901–1908 (1999).
   PubMed Web of Science ®Google Scholar
• Kays M, Brown S. Prevalence of antibacterial resistance among Streptococcus pneumoniae isolates in the USA: PROTEKT US Years 1–3. Programs and Abstracts of the Infectious Diseases Society of America Annual Meeting. Boston, MA, USA, 30 September–3 October 2004 (Abstract 354).
   Google Scholar
• Jacobs MR, Good CE, Windau AR et al. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob. Agents Chemother.54(6), 2716–2719 (2010).
   PubMed Web of Science ®Google Scholar
• Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare Fee-for-Service Program. N. Engl. J. Med.360(14), 1418–1428 (2009).
   PubMed Web of Science ®Google Scholar
• Johnson D, Carriere KC, Jin Y, Marrie T. Appropriate antibiotic utilization in seniors prior to hospitalization for community-acquired pneumonia is associated with decreased in-hospital mortality. J. Clin. Pharm. Ther.29(3), 231–239 (2004).
   PubMed Web of Science ®Google Scholar
• McCabe C, Kirchner C, Zhang H, Daley J, Fisman DN. Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. Arch. Intern. Med.169(16), 1525–1531 (2009).
   PubMed Web of Science ®Google Scholar
• Orrick JJ, Segal R, Johns TE, Russell W, Wang F, Yin DD. Resource use and cost of care for patients hospitalised with community acquired pneumonia: impact of adherence to Infectious Diseases Society of America Guidelines. PharmacoEconomics22(11), 751–757 (2004).
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J. Antimicrob. Chemother.60(2), 300–311 (2007).
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Warner M, Williams G, Critchley I, Livermore DM. Activity of chequerboard combinations of ceftaroline and NXL104 versus β-lactamase-producing Enterobacteriaceae. J. Antimicrob. Chemother.65(7), 1428–1432 (2010).
   PubMed Web of Science ®Google Scholar
• Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob. Agents Chemother.53(6), 2360–2366 (2009).
   PubMed Web of Science ®Google Scholar
• Jacqueline C, Amador G, Caillon J et al. Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis. J. Antimicrob. Chemother.65(8), 1749–1752 (2010).
   PubMed Web of Science ®Google Scholar
• Jacqueline C, Caillon J, Batard E et al. Evaluation of the in vivo efficacy of intramuscularly administered ceftaroline fosamil, a novel cephalosporin, against a methicillin-resistant Staphylococcus aureus strain in a rabbit endocarditis model. J. Antimicrob. Chemother.65(10), 2264–2265 (2010).
   PubMed Web of Science ®Google Scholar
• Jacqueline C, Caillon J, Le Mabecque V et al. In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and vancomycin. Antimicrob. Agents Chemother.53(12), 5300–5302 (2009).
   PubMed Web of Science ®Google Scholar
• Jacqueline C, Caillon J, Le Mabecque V et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob. Agents Chemother.51(9), 3397–3400 (2007).
   PubMed Web of Science ®Google Scholar